

Jerzy Jankun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8308198/publications.pdf>

Version: 2024-02-01

82
papers

2,441
citations

279487

23
h-index

223531

46
g-index

83
all docs

83
docs citations

83
times ranked

3141
citing authors

#	ARTICLE	IF	CITATIONS
1	Why drinking green tea could prevent cancer. <i>Nature</i> , 1997, 387, 561-561.	13.7	656
2	Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence.. <i>International Journal of Molecular Medicine</i> , 2000, 6, 521-6.	1.8	104
3	Determining whether curcumin degradation/condensation is actually bioactivation (Review). <i>International Journal of Molecular Medicine</i> , 2016, 37, 1151-1158.	1.8	92
4	Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 135-144.	1.2	87
5	A study of the anti-diabetic agents of camel milk. <i>International Journal of Molecular Medicine</i> , 2012, 30, 585-592.	1.8	82
6	Lipoxygenase interactions with natural flavonoid, quercetin, reveal a complex with protocatechuic acid in its X-ray structure at 2.1 Å... resolution. <i>Proteins: Structure, Function and Bioinformatics</i> , 2003, 54, 13-19.	1.5	72
7	Plasminogen activator inhibitor-1 in kidney pathology. <i>International Journal of Molecular Medicine</i> , 2013, 31, 503-510.	1.8	65
8	Human Platelet 12-Lipoxygenase, New Findings about Its Activity, Membrane Binding and Low-resolution Structure. <i>Journal of Molecular Biology</i> , 2008, 376, 193-209.	2.0	63
9	Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 Å reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. <i>International Journal of Molecular Medicine</i> , 2003, 12, 415-20.	1.8	54
10	Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. <i>BJU International</i> , 2005, 95, 1237-1244.	1.3	53
11	Structure of curcumin in complex with lipoxygenase and its significance in cancer. <i>International Journal of Molecular Medicine</i> , 2003, 12, 17-24.	1.8	52
12	Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1371-1382.	1.9	51
13	Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. <i>Oncology Reports</i> , 2001, 8, 463-70.	1.2	43
14	Clinical implications of the growth-suppressive effects of chlorhexidine at low and high concentrations on human gingival fibroblasts and changes in morphology. <i>International Journal of Molecular Medicine</i> , 2016, 37, 1594-1600.	1.8	40
15	Probing Dimerization and Structural Flexibility of Mammalian Lipoxygenases by Small-Angle X-ray Scattering. <i>Journal of Molecular Biology</i> , 2011, 409, 654-668.	2.0	37
16	Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.. <i>Oncology Reports</i> , 1999, 6, 523-6.	1.2	37
17	OPTICAL CHARACTERISTICS OF THE CANINE PROSTATE AT 665 NM SENSITIZED WITH TIN ETIOPURPURIN DICHLORIDE: NEED FOR REAL-TIME MONITORING OF PHOTODYNAMIC THERAPY. <i>Journal of Urology</i> , 2004, 172, 739-743.	0.2	35
18	Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. <i>Prostate</i> , 2006, 66, 779-787.	1.2	31

#	ARTICLE	IF	CITATIONS
19	Structural and Thermochemical Characterization of Lipoxygenase~Catechol Complexes. <i>Biochemistry</i> , 1998, 37, 17952-17957.	1.2	29
20	Inhibition of lipoxygenase by (-)-epigallocatechin gallate: X-ray analysis at 2.1 Å... reveals degradation of EGCG and shows soybean LOX-3 complex with EGC instead. <i>International Journal of Molecular Medicine</i> , 2003, 12, 415.	1.8	27
21	Lipoxygenases - A Challenging Problem in Enzyme Inhibition and Drug Development. <i>Current Enzyme Inhibition</i> , 2007, 3, 119-132.	0.3	26
22	Soybean lipoxygenase-3 in complex with 4-nitrocatechol. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 613-615.	2.5	25
23	Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review). <i>International Journal of Molecular Medicine</i> , 2011, 29, 3-11.	1.8	23
24	Computer Model for Cryosurgery of the Prostate. <i>Computer Aided Surgery</i> , 1999, 4, 193-199.	1.8	22
25	Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT. <i>Physics in Medicine and Biology</i> , 2004, 49, 3209-3225.	1.6	22
26	Unusual clotting dynamics of plasma supplemented with iron(III). <i>International Journal of Molecular Medicine</i> , 2014, 33, 367-372.	1.8	22
27	Theaflavin digallate inactivates plasminogen activator inhibitor: Could tea help in Alzheimer's disease and obesity?. <i>International Journal of Molecular Medicine</i> , 2010, 26, 45-50.	1.8	21
28	The plasminogen activation system in periodontal tissue (Review). <i>International Journal of Molecular Medicine</i> , 2014, 33, 763-768.	1.8	21
29	Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review). <i>International Journal of Molecular Medicine</i> , 2004, 13, 759-66.	1.8	21
30	Structure of curcumin in complex with lipoxygenase and its significance in cancer. <i>International Journal of Molecular Medicine</i> , 2003, 12, 17.	1.8	20
31	Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives. <i>Oncology Letters</i> , 2014, 7, 17-22.	0.8	20
32	Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review). <i>International Journal of Molecular Medicine</i> , 2019, 43, 15-25.	1.8	20
33	Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer. <i>Oncology Reports</i> , 2012, 28, 1275-1282.	1.2	19
34	Formulation and characterization of EGCG for the treatment of superficial bladder cancer. <i>International Journal of Molecular Medicine</i> , 2017, 40, 329-336.	1.8	19
35	Human platelet 12-lipoxygenase: Naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior. <i>International Journal of Molecular Medicine</i> , 2009, 24, 759-64.	1.8	17
36	Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. <i>International Journal of Oncology</i> , 2014, 44, 147-152.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?. International Journal of Molecular Sciences, 2018, 19, 248.	1.8	17
38	Nutraceutical inhibitors of urokinase: potential applications in prostate cancer prevention and treatment. Oncology Reports, 2006, 16, 341-6.	1.2	17
39	Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model. BJU International, 2010, 105, 1469-1476.	1.3	16
40	Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. International Journal of Molecular Medicine, 2011, 27, 525-9.	1.8	16
41	Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. International Journal of Molecular Medicine, 2011, 29, 61-4.	1.8	16
42	COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs.. Translation the University of Toledo Journal of Medical Sciences, 0, 7, 1-5.	0.0	16
43	Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. International Journal of Molecular Medicine, 2007, 20, 683-7.	1.8	16
44	Enamel matrix proteins exhibit growth factor activity: A review of evidence at the cellular and molecular levels. Experimental and Therapeutic Medicine, 2015, 9, 2025-2033.	0.8	14
45	Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacological Reports, 2009, 61, 673-680.	1.5	13
46	Experimental immunology Complex function of magnesium in blood clot formation and lysis. Central-European Journal of Immunology, 2013, 2, 149-153.	0.4	13
47	A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Molecular Cancer Therapeutics, 2003, 2, 19-28.	1.9	13
48	Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. International Journal of Molecular Medicine, 2010, 26, 501-4.	1.8	12
49	Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1. Experimental and Therapeutic Medicine, 2010, 1, 575-577.	0.8	12
50	Experimental immunology Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cells. Central-European Journal of Immunology, 2015, 1, 1-4.	0.4	12
51	Plasminogen activator inhibitor type-1: Its structure, biological activity and role in tumorigenesis (Review). International Journal of Molecular Medicine, 2004, 13, 759.	1.8	11
52	An Energy-Based Segmentation of Prostate from Ultrasound Images using Dot-Pattern Select Cells. , 2007, , .		11
53	Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. International Journal of Molecular Medicine, 0, , .	1.8	11
54	Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid. Experimental and Therapeutic Medicine, 2015, 9, 2339-2343.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Effects of chlorhexidine, essential oils and herbal medicines (Salvia, Chamomile, Calendula) on human fibroblast in vitro. Central-European Journal of Immunology, 2016, 2, 125-131.	0.4	11
56	Yin and yang of the plasminogen activator inhibitor. , 2009, 119, 410-7.		11
57	Plasminogen activation system in oral cancer: Relevance in prognosis and therapy (Review). International Journal of Oncology, 2015, 47, 16-24.	1.4	10
58	PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. International Journal of Molecular Medicine, 2007, 20, 11-20.	1.8	10
59	Computer model for photodynamic therapy of the prostate. , 2000, 3907, 222.		9
60	Do Human Lipoxygenases have a PDZ Regulatory Domain?. Current Molecular Medicine, 2008, 8, 768-773.	0.6	9
61	Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer. BioMed Research International, 2014, 2014, 1-7.	0.9	9
62	Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy. International Journal of Molecular Medicine, 2003, 11, 287-91.	1.8	8
63	Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncology Reports, 0, , .	1.2	7
64	Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncology Reports, 2004, 12, 1155-62.	1.2	7
65	Nutraceutical inhibitors of urokinase: Potential applications in prostate cancer prevention and treatment. Oncology Reports, 2006, 16, 341.	1.2	6
66	Protein-based nanotechnology: Antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy. International Journal of Oncology, 2011, 39, 949-53.	1.4	6
67	Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report. Experimental and Therapeutic Medicine, 2012, 4, 661-664.	0.8	6
68	Isolation and characterization of serum albumin from Camelus dromedarius. Experimental and Therapeutic Medicine, 2013, 6, 519-524.	0.8	6
69	Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients. Cardiovascular & Hematological Disorders Drug Targets, 2013, 13, 144-150.	0.2	6
70	Analysis of the inhibition of PAI-1 by metal theaflavin complexes and their degradation products. International Journal of Molecular Medicine, 2013, 31, 1153-1158.	1.8	5
71	Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. International Journal of Molecular Medicine, 2006, 17, 437-47.	1.8	5
72	Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. International Journal of Molecular Medicine, 2006, 17, 437.	1.8	4

#	ARTICLE	IF	CITATIONS
73	PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. <i>International Journal of Molecular Medicine</i> , 2007, 20, 11.	1.8	4
74	A thousand words about the challenges of photodynamic therapy. <i>Journal of Medical Science</i> , 2019, 88, 195-199.	0.2	4
75	The concentration of 12-lipoxygenase in platelet rich plasma as an indication of the cancer of the prostate. <i>Wspolczesna Onkologia</i> , 2013, 4, 389-393.	0.7	2
76	Platelet 12-lipoxygenase and stem cells in Barrett's esophagus. <i>Oncology Letters</i> , 2010, 1, 789-791.	0.8	1
77	Application of Long-Acting VLHL PAI-1 during Sutureless Partial Nephrectomy in Mice Reduces Bleeding. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	1
78	Targeting of Drugs to Tumors: The Use of the Plasminogen Activator Inhibitor as a Ligand. , 1994, , 67-79.		1
79	VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. <i>International Journal of Molecular Medicine</i> , 2009, 23, 57-63.	1.8	1
80	Control of the Aggressive Capacity of Prostate Cancer by Nutritional Inhibitors of Urokinase and Lipoxygenase. <i>International Journal of Human Genetics</i> , 2003, 3, 127-134.	0.1	0
81	Can components of the plasminogen activation system predict the outcome of kidney transplants?. <i>Central-European Journal of Immunology</i> , 2018, 43, 222-230.	0.4	0
82	If Nature Failed Creating the Perfect Prostate Could Inhibitors of Proteolysis Help?. , 2013, 02, .		0